Novel neuroprotective GSK-3β inhibitor restricts tat-mediated HIV-1 replication

Journal of Virology

Volumn 88, Issue 2, 2014, Pages 1189-1208

  Guendel, Irene ^a   Iordanskiy, Sergey ^a   Van Duyne, Rachel ^a,b   Kehn Hall, Kylene ^a   Saifuddin, Mohammed ^a   Das, Ravi ^a   Jaworski, Elizabeth ^a   Sampey, Gavin C ^a   Senina, Svetlana ^a   Shultz, Leonard ^c   Narayanan, Aarthi ^a   Chen, Hao ^d   Lepene, Benjamin ^f   Zeng, Chen ^d,e   Kashanchi, Fatah ^a  

^a GEORGE MASON UNIVERSITY   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^c JACKSON LABORATORY   (United States)

^d GEORGE WASHINGTON UNIVERSITY   (United States)

^e HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^f CERES NANOSCIENCES INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

10:5,7 DIBROMO 1H INDOLE 2,3 DIONE 3 OXIME; 18:6 CHLORO 7 METHYL 1H INDOLE 2,3 DIONE 3 OXIME; 19:4 CHLORO 7 METHYL 1H INDOLE 2,3 DIONE 3 OXIME; 6 BROMOINDIRUBIN 3' OXIME; 6:6 BROMO 5 METHYL 1H INDOLE 2,3 DIONE 3 (6 BROMO 5 METHYL 2 OXO 1,2 DIHYDRO 3H INDOL 3 YLIDENE)HYDRAZONE; FLAVOPIRIDOL; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; GLYCOGEN SYNTHASE KINASE 3BETA; OXIME DERIVATIVE; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPUTER MODEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; EMBRYO; ENZYME INHIBITION; FETUS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VITRO STUDY; IN VIVO STUDY; MICROGLIA; MOLECULAR WEIGHT; MOUSE; NERVE CELL CULTURE; NEUROPROTECTION; NEWBORN; NONHUMAN; PRIORITY JOURNAL; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS TRANSCRIPTION;

ANTI-HIV AGENTS; ENZYME INHIBITORS; GLYCOGEN SYNTHASE KINASE 3; HIV INFECTIONS; HIV-1; HUMANS; INDOLES; NEURONS; NEUROPROTECTIVE AGENTS; OXIMES; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; TRANSCRIPTION, GENETIC; VIRUS REPLICATION;

EID: 84891701581     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01940-13     Document Type: Article

References (148)

1. Ances BM, Ellis RJ. 2007. Dementia and neurocognitive disorders due to HIV-1 infection. Semin. Neurol. 27:86-92. http://dx.doi.org/10.1055/s-2006-956759.
2. Crews L, Lentz MR, Gonzalez RG, Fox HS, Masliah E. 2008. Neuronal injury in simian immunodeficiency virus and other animal models of neuroAIDS. J. Neurovirol. 14:327-339. http://dx.doi.org/10.1080/13550280802132840.
3. Heaton RK, Franklin DR, Ellis RJ, McCutchan JA, Letendre SL, Leblanc S, Corkran SH, Duarte NA, Clifford DB, Woods SP, Collier AC, Marra CM, Morgello S, Mindt MR, Taylor MJ, Marcotte TD, Atkinson JH, Wolfson T, Gelman BB, McArthur JC, Simpson DM, Abramson I, Gamst A, Fennema-Notestine C, Jernigan TL, Wong J, Grant I. 2011. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J. Neurovirol. 17:3-16. http://dx.doi.org/10.1007/s13365-010-0006-1.
4. McArthur JC, Brew BJ, Nath A. 2005. Neurological complications of HIV infection. Lancet Neurol. 4:543-555. http://dx.doi.org/10.1016/S1474-4422(05)70165-4.
5. McArthur JC, Brew BJ. 2010. HIV-associated neurocognitive disorders: is there a hidden epidemic? AIDS 24:1367-1370. http://dx.doi.org/10.1097/QAD.0b013e3283391d56.
6. Zou S, El-Hage N, Podhaizer EM, Knapp PE, Hauser KF. 2011. PTEN gene silencing prevents HIV-1 gp120(IIIB)-induced degeneration of striatal neurons. J. Neurovirol. 17:41-49. http://dx.doi.org/10.1007/s13365-010-0016-z.
7. Ju SM, Goh AR, Kwon DJ, Youn GS, Kwon HJ, Bae YS, Choi SY, Park J. 2012. Extracellular HIV-1 Tat induces human beta-defensin-2 production via NF-kappaB/AP-1 dependent pathways in human B cells. Mol. Cells 33:335-341. http://dx.doi.org/10.1007/s10059-012-2287-0.
8. Thakur BK, Chandra A, Dittrich T, Welte K, Chandra P. 2012. Inhibition of SIRT1 by HIV-1 viral protein Tat results in activation of p53 pathway. Biochem. Biophys. Res. Commun. 424:245-250. http://dx.doi.org/10.1016/j.bbrc.2012.06.084.
9. Kim SE, Lee EO, Yang JH, Kang JH, Suh YH, Chong YH. 2012. 15-Deoxy-delta(1)(2),(1)(4)-prostaglandin J(2) inhibits human immunodeficiency virus-1 Tat-induced monocyte chemoattractant protein-1/CCL2 production by blocking the extracellular signal-regulated kinase-1/2 signaling pathway independently of peroxisome proliferatoractivated receptor-gamma and heme oxygenase-1 in rat hippocampal slices. J. Neurosci. Res. 90:1732-1742. http://dx.doi.org/10.1002/jnr.23051.
10. Bachis A, Avdoshina V, Zecca L, Parsadanian M, Mocchetti I. 2012. Human immunodeficiency virus type 1 alters brain-derived neurotrophic factor processing in neurons. J. Neurosci. 32:9477-9484. http://dx.doi.org/10.1523/JNEUROSCI.0865-12.2012.
11. Reddy PV, Gandhi N, Samikkannu T, Saiyed Z, Agudelo M, Yndart A, Khatavkar P, Nair MP. 2012. HIV-1 gp120 induces antioxidant response element-mediated expression in primary astrocytes: role in HIV associated neurocognitive disorder. Neurochem Int. 61:807-814. http://dx.doi.org/10.1016/j.neuint.2011.06.011.
12. Fujinaga K, Cujec TP, Peng J, Garriga J, Price DH, Grana X, Peterlin BM. 1998. The ability of positive transcription elongation factor B to transactivate human immunodeficiency virus transcription depends on a functional kinase domain, cyclin T1, and Tat. J. Virol. 72:7154-7159.
13. Herrmann CH, Rice AP. 1995. Lentivirus Tat proteins specifically associate with a cellular protein kinase, TAK, that hyperphosphorylates the carboxyl-terminal domain of the large subunit of RNA polymerase II: candidate for a Tat cofactor. J. Virol. 69:1612-1620.
14. Laspia MF, Rice AP, Mathews MB. 1989. HIV-1 Tat protein increases transcriptional initiation and stabilizes elongation. Cell 59:283-292. http://dx.doi.org/10.1016/0092-8674(89)90290-0.
15. Nabel G, Baltimore D. 1987. An inducible transcription factor activates expression of human immunodeficiency virus in T cells. Nature 326:711-713. http://dx.doi.org/10.1038/326711a0.
16. Peng J, Zhu Y, Milton JT, Price DH. 1998. Identification of multiple cyclin subunits of human P-TEFb. Genes Dev. 12:755-762. http://dx.doi.org/10.1101/gad.12.5.755.
17. Rice AP, Mathews MB. 1988. Transcriptional but not translational regulation of HIV-1 by the tat gene product. Nature 332:551-553. http://dx.doi.org/10.1038/332551a0.
18. Sobhian B, Laguette N, Yatim A, Nakamura M, Levy Y, Kiernan R, Benkirane M. 2010. HIV-1 Tat assembles a multifunctional transcription elongation complex and stably associates with the 7SK snRNP. Mol. Cell 38:439-451. http://dx.doi.org/10.1016/j.molcel.2010.04.012.
19. Wei P, Garber ME, Fang SM, Fischer WH, Jones KA. 1998. A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA. Cell 92:451-462. http://dx.doi.org/10.1016/S0092-8674(00)80939-3.
20. Ensoli B, Buonaguro L, Barillari G, Fiorelli V, Gendelman R, Morgan RA, Wingfield P, Gallo RC. 1993. Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation. J. Virol. 67:277-287.
21. Chihara T, Hashimoto M, Osman A, Hiyoshi-Yoshidomi Y, Suzu I, Chutiwitoonchai N, Hiyoshi M, Okada S, Suzu S. 2012. HIV-1 proteins preferentially activate anti-inflammatory M2-type macrophages. J. Immunol. 188:3620-3627. http://dx.doi.org/10.4049/jimmunol.1101593.
22. Pocernich CB, Boyd-Kimball D, Poon HF, Thongboonkerd V, Lynn BC, Klein JB, Calebrese V, Nath A, Butterfield DA. 2005. Proteomics analysis of human astrocytes expressing the HIV protein Tat. Brain Res. Mol. Brain Res. 133:307-316. http://dx.doi.org/10.1016/j.molbrainres.2004.10.023.
23. Deshmane SL, Mukerjee R, Fan S, Sawaya BE. 2011. High-performance capillary electrophoresis for determining HIV-1 Tat protein in neurons. PLoS One 6:e16148. http://dx.doi.org/10.1371/journal.pone.0016148.
24. Rayne F, Debaisieux S, Yezid H, Lin YL, Mettling C, Konate K, Chazal N, Arold ST, Pugniere M, Sanchez F, Bonhoure A, Briant L, Loret E, Roy C, Beaumelle B. 2010. Phosphatidylinositol-(4,5)-bisphosphate enables efficient secretion of HIV-1 Tat by infected T-cells. EMBO J. 29:1348-1362. http://dx.doi.org/10.1038/emboj.2010.32.
25. Xiao H, Neuveut C, Tiffany HL, Benkirane M, Rich EA, Murphy PM, Jeang KT. 2000. Selective CXCR4 antagonism by Tat: implications for in vivo expansion of coreceptor use by HIV-1. Proc. Natl. Acad. Sci. U. S. A. 97:11466-11471. http://dx.doi.org/10.1073/pnas.97.21.11466.
26. Johnson TP, Patel K, Johnson KR, Maric D, Calabresi PA, Hasbun R, Nath A. 2013. Induction of IL-17 and nonclassical T-cell activation by HIV-Tat protein. Proc. Natl. Acad. Sci. U. S. A. 110:13588-13593. http://dx.doi.org/10.1073/pnas.1308673110.
27. Cheng J, Nath A, Knudsen B, Hochman S, Geiger JD, Ma M, Magnuson DS. 1998. Neuronal excitatory properties of human immunodeficiency virus type 1 Tat protein. Neuroscience 82:97-106.
28. Bennett BA, Rusyniak DE, Hollingsworth CK. 1995. HIV-1 gp120-induced neurotoxicity to midbrain dopamine cultures. Brain Res. 705:168-176. http://dx.doi.org/10.1016/0006-8993(95)01166-8.
29. Magnuson DS, Knudsen BE, Geiger JD, Brownstone RM, Nath A. 1995. Human immunodeficiency virus type 1 tat activates non-N-methyl-D-aspartate excitatory amino acid receptors and causes neurotoxicity. Ann. Neurol. 37:373-380. http://dx.doi.org/10.1002/ana.410370314.
30. Maragos WF, Tillman P, Jones M, Bruce-Keller AJ, Roth S, Bell JE, Nath A. 2003. Neuronal injury in hippocampus with human immunodeficiency virus transactivating protein, Tat. Neuroscience 117:43-53. http://dx.doi.org/10.1016/S0306-4522(02)00713-3.
31. Sabatier JM, Vives E, Mabrouk K, Benjouad A, Rochat H, Duval A, Hue B, Bahraoui E. 1991. Evidence for neurotoxic activity of tat from human immunodeficiency virus type 1. J. Virol. 65:961-967.
32. Weeks BS, Lieberman DM, Johnson B, Roque E, Green M, Loewenstein P, Oldfield EH, Kleinman HK. 1995. Neurotoxicity of the human immunodeficiency virus type 1 tat transactivator to PC12 cells requires the Tat amino acid 49-58 basic domain. J. Neurosci. Res. 42:34-40. http://dx.doi.org/10.1002/jnr.490420105.
33. Kehn-Hall K, Guendel I, Carpio L, Skaltsounis L, Meijer L, Al-Harthi L, Steiner JP, Nath A, Kutsch O, Kashanchi F. 2011. Inhibition of Tat-mediated HIV-1 replication and neurotoxicity by novel GSK3-beta inhibitors. Virology 415:56-68. http://dx.doi.org/10.1016/j.virol.2011.03.025.
34. Kruman II, Nath A, Mattson MP. 1998. HIV-1 protein Tat induces apoptosis of hippocampal neurons by a mechanism involving caspase activation, calcium overload, and oxidative stress. Exp. Neurol. 154:276-288. http://dx.doi.org/10.1006/exnr.1998.6958.
35. Haughey NJ, Holden CP, Nath A, Geiger JD. 1999. Involvement of inositol 1,4,5-trisphosphate-regulated stores of intracellular calcium in calcium dysregulation and neuron cell death caused by HIV-1 protein tat. J. Neurochem. 73:1363-1374.
36. Aksenov MY, Hasselrot U, Bansal AK, Wu G, Nath A, Anderson C, Mactutus CF, Booze RM. 2001. Oxidative damage induced by the injection of HIV-1 Tat protein in the rat striatum. Neurosci. Lett. 305:5-8. http://dx.doi.org/10.1016/S0304-3940(01)01786-4.
37. Aksenov MY, Hasselrot U, Wu G, Nath A, Anderson C, Mactutus CF, Booze RM. 2003. Temporal relationships between HIV-1 Tat-induced neuronal degeneration, OX-42 immunoreactivity, reactive astrocytosis, and protein oxidation in the rat striatum. Brain Res. 987:1-9. http://dx.doi.org/10.1016/S0006-8993(03)03194-9.
38. Bansal AK, Mactutus CF, Nath A, Maragos W, Hauser KF, Booze RM. 2000. Neurotoxicity of HIV-1 proteins gp120 and Tat in the rat striatum. Brain Res. 879:42-49. http://dx.doi.org/10.1016/S0006-8993(00)02725-6.
39. Nath A, Haughey NJ, Jones M, Anderson C, Bell JE, Geiger JD. 2000. Synergistic neurotoxicity by human immunodeficiency virus proteins Tat and gp120: protection by memantine. Ann. Neurol. 47:186-194. http://dx.doi.org/10.1002/1531-8249(200002)47:2.186::AID-ANA8.3.0.CO;2-3.
40. Polazzi E, Levi G, Minghetti L. 1999. Human immunodeficiency virus type 1 Tat protein stimulates inducible nitric oxide synthase expression and nitric oxide production in microglial cultures. J. Neuropathol. Exp. Neurol. 58:825-831. http://dx.doi.org/10.1097/00005072-199908000-00005.
41. Gavriil ES, Cooney R, Weeks BS. 2000. Tat mediates apoptosis in vivo in the rat central nervous system. Biochem. Biophys. Res. Commun. 267:252-256. http://dx.doi.org/10.1006/bbrc.1999.1894.
42. Haughey NJ, Nath A, Mattson MP, Slevin JT, Geiger JD. 2001. HIV-1 Tat through phosphorylation of NMDA receptors potentiates glutamate excitotoxicity. J. Neurochem. 78:457-467. http://dx.doi.org/10.1046/j.1471-4159.2001.00396.x.
43. Noonan D, Albini A. 2000. From the outside in: extracellular activities of HIV Tat. Adv. Pharmacol. 48:229-250. http://dx.doi.org/10.1016/S1054-3589(00)48008-7.
44. Rusnati M, Presta M. 2002. HIV-1 Tat protein and endothelium: from protein/cell interaction to AIDS-associated pathologies. Angiogenesis 5:141-151. http://dx.doi.org/10.1023/A:1023892223074.
45. Krum JM, Rosenstein JM. 1998. VEGF mRNA and its receptor flt-1 are expressed in reactive astrocytes following neural grafting and tumor cell implantation in the adult CNS. Exp. Neurol. 154:57-65. http://dx.doi.org/10.1006/exnr.1998.6930.
46. Barillari G, Gendelman R, Gallo RC, Ensoli B. 1993. The Tat protein of human immunodeficiency virus type 1, a growth factor for AIDS Kaposi sarcoma and cytokine-activated vascular cells, induces adhesion of the same cell types by using integrin receptors recognizing the RGD amino acid sequence. Proc. Natl. Acad. Sci. U. S. A. 90:7941-7945. http://dx.doi.org/10.1073/pnas.90.17.7941.
47. Etienne-Manneville S, Hall A. 2001. Integrin-mediated activation of Cdc42 controls cell polarity in migrating astrocytes through PKCzeta. Cell 106:489-498. http://dx.doi.org/10.1016/S0092-8674(01)00471-8.
48. Liu Y, Jones M, Hingtgen CM, Bu G, Laribee N, Tanzi RE, Moir RD, Nath A, He JJ. 2000. Uptake of HIV-1 tat protein mediated by lowdensity lipoprotein receptor-related protein disrupts the neuronal metabolic balance of the receptor ligands. Nat. Med. 6:1380-1387. http://dx.doi.org/10.1038/82199.
49. Haughey NJ, Mattson MP. 2002. Calcium dysregulation and neuronal apoptosis by the HIV-1 proteins Tat and gp120. J. Acquir. Immune Defic. Syndr 31(Suppl 2):S55-S61. http://dx.doi.org/10.1097/00126334-200210012-00005.
50. Nath A, Psooy K, Martin C, Knudsen B, Magnuson DS, Haughey N, Geiger JD. 1996. Identification of a human immunodeficiency virus type 1 Tat epitope that is neuroexcitatory and neurotoxic. J. Virol. 70:1475-1480.
51. Toggas SM, Masliah E, Mucke L. 1996. Prevention of HIV-1 gp120-induced neuronal damage in the central nervous system of transgenic mice by the NMDA receptor antagonist memantine. Brain Res. 706:303-307. http://dx.doi.org/10.1016/0006-8993(95)01197-8.
52. Wu P, Price P, Du B, Hatch WC, Terwilliger EF. 1996. Direct cytotoxicity of HIV-1 envelope protein gp120 on human NT neurons. Neuroreport 7:1045-1049. http://dx.doi.org/10.1097/00001756-199604100-00018.
53. Holden CP, Haughey NJ, Nath A, Geiger JD. 1999. Role of Na+/H+ exchangers, excitatory amino acid receptors and voltage-operated Ca2+ channels in human immunodeficiency virus type 1 gp120-mediated increases in intracellular Ca2+ in human neurons and astrocytes. Neuroscience 91:1369-1378. http://dx.doi.org/10.1016/S0306-4522(98)00714-3.
54. Khurdayan VK, Buch S, El-Hage N, Lutz SE, Goebel SM, Singh IN, Knapp PE, Turchan-Cholewo J, Nath A, Hauser KF. 2004. Preferential vulnerability of astroglia and glial precursors to combined opioid and HIV-1 Tat exposure in vitro. Eur. J. Neurosci. 19:3171-3182. http://dx.doi.org/10.1111/j.0953-816X.2004.03461.x.
55. Muller WE, Pergande G, Ushijima H, Schleger C, Kelve M, Perovic S. 1996. Neurotoxicity in rat cortical cells caused by N-methyl-D-aspartate (NMDA) and gp120 of HIV-1: induction and pharmacological intervention. Prog. Mol. Subcell. Biol. 16:44-57. http://dx.doi.org/10.1007/978-3-642-79850-4_3.
56. Chao CC, Hu S, Gekker G, Lokensgard JR, Heyes MP, Peterson PK. 2000. U50,488 protection against HIV-1-related neurotoxicity: involvement of quinolinic acid suppression. Neuropharmacology 39:150-160. http://dx.doi.org/10.1016/S0028-3908(99)00063-5.
57. Wallace DR, Dodson SL, Nath A, Booze RM. 2006. Delta opioid agonists attenuate TAT(1-72)-induced oxidative stress in SK-N-SH cells. Neurotoxicology 27:101-107. http://dx.doi.org/10.1016/j.neuro.2005.07.008.
58. Pulliam L, Irwin I, Kusdra L, Rempel H, Flitter WD, Garland WA. 2001. CPI-1189 attenuates effects of suspected neurotoxins associated with AIDS dementia: a possible role for ERK activation. Brain Res. 893:95-103. http://dx.doi.org/10.1016/S0006-8993(00)03293-5.
59. Everall IP, Bell C, Mallory M, Langford D, Adame A, Rockestein E, Masliah E. 2002. Lithium ameliorates HIV-gp120-mediated neurotoxicity. Mol. Cell Neurosci. 21:493-501. http://dx.doi.org/10.1006/mcne.2002.1196.
60. Hamy F, Brondani V, Florsheimer A, Stark W, Blommers MJ, Klimkait T. 1998. A new class of HIV-1 Tat antagonist acting through Tat-TAR inhibition. Biochemistry 37:5086-5095. http://dx.doi.org/10.1021/bi972947s.
61. Bailly C, Colson P, Houssier C, Hamy F. 1996. The binding mode of drugs to the TAR RNA of HIV-1 studied by electric linear dichroism. Nucleic Acids Res. 24:1460-1464. http://dx.doi.org/10.1093/nar/24.8.1460.
62. Dassonneville L, Hamy F, Colson P, Houssier C, Bailly C. 1997. Binding of Hoechst 33258 to the TAR RNA of HIV-1. Recognition of a pyrimidine bulge-dependent structure. Nucleic Acids Res. 25:4487-4492.
63. Edwards TE, Sigurdsson ST. 2002. Electron paramagnetic resonance dynamic signatures of TAR RNA-small molecule complexes provide insight into RNA structure and recognition. Biochemistry 41:14843-14847. http://dx.doi.org/10.1021/bi026299a.
64. Mestre B, Arzumanov A, Singh M, Boulme F, Litvak S, Gait MJ. 1999. Oligonucleotide inhibition of the interaction of HIV-1 Tat protein with the trans-activation responsive region (TAR) of HIV RNA. Biochim. Biophys. Acta 1445:86-98. http://dx.doi.org/10.1016/S0167-4781(99)00019-6.
65. Baba M, Okamoto M, Makino M, Kimura Y, Ikeuchi T, Sakaguchi T, Okamoto T. 1997. Potent and selective inhibition of human immunodeficiency virus type 1 transcription by piperazinyloxoquinoline derivatives. Antimicrob. Agents Chemother. 41:1250-1255.
66. Baba M, Okamoto M, Kawamura M, Makino M, Higashida T, Takashi T, Kimura Y, Ikeuchi T, Tetsuka T, Okamoto T. 1998. Inhibition of human immunodeficiency virus type 1 replication and cytokine production by fluoroquinoline derivatives. Mol. Pharmacol. 53:1097-1103.
67. Hsu MC, Dhingra U, Earley JV, Holly M, Keith D, Nalin CM, Richou AR, Schutt AD, Tam SY, Potash MJ. 1993. Inhibition of type 1 human immunodeficiency virus replication by a tat antagonist to which the virus remains sensitive after prolonged exposure in vitro. Proc. Natl. Acad. Sci. U. S. A. 90:6395-6399. http://dx.doi.org/10.1073/pnas.90.14.6395.
68. Haubrich RH, Flexner C, Lederman MM, Hirsch M, Pettinelli CP, Ginsberg R, Lietman P, Hamzeh FM, Spector SA, Richman DD. 1995. A randomized trial of the activity and safety of Ro 24-7429 (Tat antagonist) versus nucleoside for human immunodeficiency virus infection. The AIDS Clinical Trials Group 213 Team. J. Infect. Dis. 172:1246-1252.
69. Agbottah E, de La Fuente C, Nekhai S, Barnett A, Gianella-Borradori A, Pumfery A, Kashanchi F. 2005. Antiviral activity of CYC202 in HIV-1-infected cells. J. Biol. Chem. 280:3029-3042. http://dx.doi.org/10.1074/jbc.M406435200.
70. Galons H, Oumata N, Meijer L. 2010. Cyclin-dependent kinase inhibitors: a survey of recent patent literature. Expert Opin. Ther. Pat. 20:377-404. http://dx.doi.org/10.1517/13543770903524284.
71. Kashanchi F, Kehn-Hall K. 2009. Cyclin dependent kinases as attractive targets to prevent transcription from viral genomes. Curr. Pharm. Des. 15:2520-2532. http://dx.doi.org/10.2174/138161209788682280.
72. Guendel I, Agbottah ET, Kehn-Hall K, Kashanchi F. 2010. Inhibition of human immunodeficiency virus type-1 by cdk inhibitors. AIDS Res. Ther. 7:7. http://dx.doi.org/10.1186/1742-6405-7-7.
73. Malumbres M, Pevarello P, Barbacid M, Bischoff JR. 2008. CDK inhibitors in cancer therapy: what is next? Trends Pharmacol. Sci. 29:16-21. http://dx.doi.org/10.1016/j.tips.2007.10.012.
74. Van Duyne R, Cardenas J, Easley R, Wu W, Kehn-Hall K, Klase Z, Mendez S, Zeng C, Chen H, Saifuddin M, Kashanchi F. 2008. Effect of transcription peptide inhibitors on HIV-1 replication. Virology 376:308-322. http://dx.doi.org/10.1016/j.virol.2008.02.036.
75. Narayanan A, Sampey G, Van Duyne R, Guendel I, Kehn-Hall K, Roman J, Currer R, Galons H, Oumata N, Joseph B, Meijer L, Caputi M, Nekhai S, Kashanchi F. 2012. Use of ATP analogs to inhibit HIV-1 transcription. Virology 432:219-231. http://dx.doi.org/10.1016/j.virol.2012.06.007.
76. Dou H, Birusingh K, Faraci J, Gorantla S, Poluektova LY, Maggirwar SB, Dewhurst S, Gelbard HA, Gendelman HE. 2003. Neuroprotective activities of sodium valproate in a murine model of human immunodeficiency virus-1 encephalitis. J. Neurosci. 23:9162-9170.
77. Dou H, Ellison B, Bradley J, Kasiyanov A, Poluektova LY, Xiong H, Maggirwar S, Dewhurst S, Gelbard HA, Gendelman HE. 2005. Neuroprotective mechanisms of lithium in murine human immunodeficiency virus-1 encephalitis. J. Neurosci. 25:8375-8385. http://dx.doi.org/10.1523/JNEUROSCI.2164-05.2005.
78. Nguyen TB, Lucero GR, Chana G, Hult BJ, Tatro ET, Masliah E, Grant I, Achim CL, Everall IP. 2009. Glycogen synthase kinase-3beta (GSK-3beta) inhibitors AR-A014418 and B6B3O prevent human immunodeficiency virus-mediated neurotoxicity in primaryhumanneurons. J. Neurovirol. 15:434-438. http://dx.doi.org/10.3109/13550280903168131.
79. Atanassov CL, Muller CD, Dumont S, Rebel G, Poindron P, Seiler N. 1995. Effect of ammonia on endocytosis and cytokine production by immortalized human microglia and astroglia cells. Neurochem Int. 27:417-424. http://dx.doi.org/10.1016/0197-0186(95)00023-2.
80. Peudenier S, Hery C, Montagnier L, Tardieu M. 1991. Human microglial cells: characterization in cerebral tissue and in primary culture, and study of their susceptibility to HIV-1 infection. Ann. Neurol. 29:152-161. http://dx.doi.org/10.1002/ana.410290207.
81. de Gannes FM, Merle M, Canioni P, Voisin PJ. 1998. Metabolic and cellular characterization of immortalized human microglial cells under heat stress. Neurochem Int. 33:61-73. http://dx.doi.org/10.1016/S0197-0186(05)80010-5.
82. Derdeyn CA, Decker JM, Sfakianos JN, Wu X, O'Brien WA, Ratner L, Kappes JC, Shaw GM, Hunter E. 2000. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J. Virol. 74:8358-8367. http://dx.doi.org/10.1128/JVI.74.18.8358-8367.2000.
83. Berro R, Kehn K, de la Fuente C, Pumfery A, Adair R, Wade J, Colberg-Poley AM, Hiscott J, Kashanchi F. 2006. Acetylated Tat regulates human immunodeficiency virus type 1 splicing through its interaction with the splicing regulator p32. J. Virol. 80:3189-3204. http://dx.doi.org/10.1128/JVI.80.7.3189-3204.2006.
84. Perez VL, Rowe T, Justement JS, Butera ST, June CH, Folks TM. 1991. An HIV-1-infected T cell clone defective in IL-2 production and Ca2+ mobilization after CD3 stimulation. J. Immunol. 147:3145-3148.
85. Clouse KA, Powell D, Washington I, Poli G, Strebel K, Farrar W, Barstad P, Kovacs J, Fauci AS, Folks TM. 1989. Monokine regulation of human immunodeficiency virus-1 expression in a chronically infected human T cell clone. J. Immunol. 142:431-438.
86. Folks TM, Justement J, Kinter A, Dinarello CA, Fauci AS. 1987. Cytokine-induced expression of HIV-1 in a chronically infected promonocyte cell line. Science 238:800-802. http://dx.doi.org/10.1126/science.3313729.
87. Murrell JR, Hunter DD. 1999. An olfactory sensory neuron line, odora, properly targets olfactory proteins and responds to odorants. J. Neurosci. 19:8260-8270.
88. Kashanchi F, Duvall JF, Brady JN. 1992. Electroporation of viral transactivator proteins into lymphocyte suspension cells. Nucleic Acids Res. 20:4673-4674. http://dx.doi.org/10.1093/nar/20.17.4673.
89. Schuttelkopf AW, van Aalten DM. 2004. PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr. D Biol. Crystallogr. 60:1355-1363. http://dx.doi.org/10.1107/S0907444904011679.
90. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE. 2004. UCSF Chimera-a visualization system for exploratory research and analysis. J. Comput. Chem. 25:1605-1612. http://dx.doi.org/10.1002/jcc.20084.
91. Wallace AC, Laskowski RA, Thornton JM. 1995. LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng. 8:127-134. http://dx.doi.org/10.1093/protein/8.2.127.
92. Carpio L, Klase Z, Coley W, Guendel I, Choi S, Van Duyne R, Narayanan A, Kehn-Hall K, Meijer L, Kashanchi F. 2010. microRNA machinery is an integral component of drug-induced transcription inhibition in HIV-1 infection. J. RNAi Gene Silencing 6:386-400.
93. Tamburro D, Fredolini C, Espina V, Douglas TA, Ranganathan A, Ilag L, Zhou W, Russo P, Espina BH, Muto G, Petricoin EF, III, Liotta LA, Luchini A. 2011. Multifunctional core-shell nanoparticles: discovery of previously invisible biomarkers. J. Am. Chem. Soc. 133:19178-19188. http://dx.doi.org/10.1021/ja207515j.
94. Luchini A, Geho DH, Bishop B, Tran D, Xia C, Dufour RL, Jones CD, Espina V, Patanarut A, Zhou W, Ross MM, Tessitore A, Petricoin EF, III, Liotta LA. 2008. Smart hydrogel particles: biomarker harvesting: one-step affinity purification, size exclusion, and protection against degradation. Nano Lett. 8:350-361. http://dx.doi.org/10.1021/nl072174l.
95. Kehn-Hall K, Narayanan A, Lundberg L, Sampey G, Pinkham C, Guendel I, Van Duyne R, Senina S, Schultz KL, Stavale E, Aman MJ, Bailey C, Kashanchi F. 2012. Modulation of GSK-3beta activity in Venezuelan equine encephalitis virus infection. PLoS One 7:e34761. http://dx.doi.org/10.1371/journal.pone.0034761.
96. Spokoini R, Kfir-Erenfeld S, Yefenof E, Sionov RV. 2010. Glycogen synthase kinase-3 plays a central role in mediating glucocorticoid-induced apoptosis. Mol. Endocrinol. 24:1136-1150. http://dx.doi.org/10.1210/me.2009-0466.
97. Li M, Wang X, Meintzer MK, Laessig T, Birnbaum MJ, Heidenreich KA. 2000. Cyclic AMP promotes neuronal survival by phosphorylation of glycogen synthase kinase 3beta. Mol. Cell. Biol. 20:9356-9363. http://dx.doi.org/10.1128/MCB.20.24.9356-9363.2000.
98. Chin PC, Majdzadeh N, D'Mello SR. 2005. Inhibition of GSK3beta is a common event in neuroprotection by different survival factors. Brain Res. Mol. Brain Res. 137:193-201. http://dx.doi.org/10.1016/j.molbrainres.2005.03.004.
99. Cao H, Chu Y, Lv X, Qiu P, Liu C, Zhang H, Li D, Peng S, Dou Z, Hua J. 2012. GSK3 inhibitor-BIO regulates proliferation of immortalized pancreatic mesenchymal stem cells (iPMSCs). PLoS One 7:e31502. http://dx.doi.org/10.1371/journal.pone.0031502.
100. Chao SH, Fujinaga K, Marion JE, Taube R, Sausville EA, Senderowicz AM, Peterlin BM, Price DH. 2000. Flavopiridol inhibits P-TEFb and blocks HIV-1 replication. J. Biol. Chem. 275:28345-28348. http://dx.doi.org/10.1074/jbc.C000446200.
101. Coley W, Van Duyne R, Carpio L, Guendel I, Kehn-Hall K, Chevalier S, Narayanan A, Luu T, Lee N, Klase Z, Kashanchi F. 2010. Absence of DICER in monocytes and its regulation by HIV-1. J. Biol. Chem. 285:31930-31943. http://dx.doi.org/10.1074/jbc.M110.101709.
102. Del Bufalo A, Bernad J, Dardenne C, Verda D, Meunier JR, Rousset F, Martinozzi-Teissier S, Pipy B. 2011. Contact sensitizers modulate the arachidonic acid metabolism of PMA-differentiated U-937 monocytic cells activated by LPS. Toxicol. Appl. Pharmacol. 256:35-43. http://dx.doi.org/10.1016/j.taap.2011.06.025.
103. Meares GP, Jope RS. 2007. Resolution of the nuclear localization mechanism of glycogen synthase kinase-3: functional effects in apoptosis. J. Biol. Chem. 282:16989-17001. http://dx.doi.org/10.1074/jbc.M700610200.
104. Kim YK, Mbonye U, Hokello J, Karn J. 2011. T-cell receptor signaling enhances transcriptional elongation from latent HIV proviruses by activating P-TEFb through an ERK-dependent pathway. J. Mol. Biol. 410:896-916. http://dx.doi.org/10.1016/j.jmb.2011.03.054.
105. Van Duyne R, Guendel I, Narayanan A, Gregg E, Shafagati N, Tyagi M, Easley R, Klase Z, Nekhai S, Kehn-Hall K, Kashanchi F. 2011. Varying modulation of HIV-1 LTR activity by Baf complexes. J. Mol. Biol. 411:581-596. http://dx.doi.org/10.1016/j.jmb.2011.06.001.
106. Spear M, Guo J, Wu Y. 2012. The trinity of the cortical actin in the initiation of HIV-1 infection. Retrovirology. 9:45. http://dx.doi.org/10.1186/1742-4690-9-45.
107. Jung DJ, Sung HS, Goo YW, Lee HM, Park OK, Jung SY, Lim J, Kim HJ, Lee SK, Kim TS, Lee JW, Lee YC. 2002. Novel transcription coactivator complex containing activating signal cointegrator 1. Mol. Cell. Biol. 22:5203-5211. http://dx.doi.org/10.1128/MCB.22.14.5203-5211.2002.
108. Carlson B, Lahusen T, Singh S, Loaiza-Perez A, Worland PJ, Pestell R, Albanese C, Sausville EA, Senderowicz AM. 1999. Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol. Cancer Res. 59:4634-4641.
109. Kanazawa S, Okamoto T, Peterlin BM. 2000. Tat competes with CIITA for the binding to P-TEFb and blocks the expression of MHC class II genes in HIV infection. Immunity 12:61-70. http://dx.doi.org/10.1016/S1074-7613(00)80159-4.
110. Chao SH, Walker JR, Chanda SK, Gray NS, Caldwell JS. 2003. Identification of homeodomain proteins, PBX1 and PREP1, involved in the transcription of murine leukemia virus. Mol. Cell. Biol. 23:831-841. http://dx.doi.org/10.1128/MCB.23.3.831-841.2003.
111. Grimes CA, Jope RS. 2001. The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog. Neurobiol. 65:391-426. http://dx.doi.org/10.1016/S0301-0082(01)00011-9.
112. Boska MD, Mosley RL, Nawab M, Nelson JA, Zelivyanskaya M, Poluektova L, Uberti M, Dou H, Lewis TB, Gendelman HE. 2004. Advances in neuroimaging for HIV-1 associated neurological dysfunction: clues to the diagnosis, pathogenesis and therapeutic monitoring. Curr. HIV Res. 2:61-78. http://dx.doi.org/10.2174/1570162043485095.
113. Nath A, Geiger J. 1998. Neurobiological aspects of human immunodeficiency virus infection: neurotoxic mechanisms. Prog. Neurobiol. 54:19-33. http://dx.doi.org/10.1016/S0301-0082(97)00053-1.
114. Piller SC, Jans P, Gage PW, Jans DA. 1998. Extracellular HIV-1 virus protein R causes a large inward current and cell death in cultured hippocampal neurons: implications for AIDS pathology. Proc. Natl. Acad. Sci. U. S. A. 95:4595-4600. http://dx.doi.org/10.1073/pnas.95.8.4595.
115. Reddy PV, Gandhi N, Samikkannu T, Saiyed Z, Agudelo M, Yndart A, Khatavkar P, Nair MP. 2012. HIV-1 gp120 induces antioxidant response element-mediated expression in primary astrocytes: role in HIV associated neurocognitive disorder. Neurochem Int. 61:807-814. http://dx.doi.org/10.1016/j.neuint.2011.06.011.
116. Li W, Li G, Steiner J, Nath A. 2009. Role of Tat protein in HIV neuropathogenesis. Neurotox. Res. 16:205-220. http://dx.doi.org/10.1007/s12640-009-9047-8.
117. Chauhan A, Turchan J, Pocernich C, Bruce-Keller A, Roth S, Butterfield DA, Major EO, Nath A. 2003. Intracellular human immunodeficiency virus Tat expression in astrocytes promotes astrocyte survival but induces potent neurotoxicity at distant sites via axonal transport. J. Biol. Chem. 278:13512-13519. http://dx.doi.org/10.1074/jbc.M209381200.
118. Zhong J, Yao W, Lee W. 2007. Cesium chloride protects cerebellar granule neurons from apoptosis induced by low potassium. Int. J. Dev. Neurosci. 25:359-365. http://dx.doi.org/10.1016/j.ijdevneu.2007.07.003.
119. Cross DA, Culbert AA, Chalmers KA, Facci L, Skaper SD, Reith AD. 2001. Selective small-molecule inhibitors of glycogen synthase kinase-3 activity protect primary neurones from death. J. Neurochem. 77:94-102. http://dx.doi.org/10.1046/j.1471-4159.2001.t01-1-00251.x.
120. Villalba M, Bockaert J, Journot L. 1997. Pituitary adenylate cyclaseactivating polypeptide (PACAP-38) protects cerebellar granule neurons from apoptosis by activating the mitogen-activated protein kinase (MAP kinase) pathway. J. Neurosci. 17:83-90.
121. Van Duyne R, Guendel I, Jaworski E, Sampey G, Klase Z, Chen H, Zeng C, Kovalskyy D, El Kouni MH, Lepene B, Patanarut A, Nekhai S, Price DH, Kashanchi F. 2013. Effect of mimetic CDK9 inhibitors on HIV-1-activated transcription. J. Mol. Biol. 425:812-829. http://dx.doi.org/10.1016/j.jmb.2012.12.005.
122. Jaeger LB, Nath A. 2012. Modeling HIV-associated neurocognitive disorders in mice: new approaches in the changing face of HIV neuropathogenesis. Dis. Model Mech. 5:313-322. http://dx.doi.org/10.1242/dmm.008763.
123. Taylor DD, Zacharias W, Gercel-Taylor C. 2011. Exosome isolation for proteomic analyses and RNA profiling. Methods Mol. Biol. 728:235-246. http://dx.doi.org/10.1007/978-1-61779-068-3_15.
124. Blanpain C, Libert F, Vassart G, Parmentier M. 2002. CCR5 and HIV infection. Receptors Channels 8:19-31. http://dx.doi.org/10.1080/10606820212135.
125. King JE, Eugenin EA, Buckner CM, Berman JW. 2006. HIV tat and neurotoxicity. Microbes Infect. 8:1347-1357. http://dx.doi.org/10.1016/j.micinf.2005.11.014.
126. Meijer L, Skaltsounis AL, Magiatis P, Polychronopoulos P, Knockaert M, Leost M, Ryan XP, Vonica CA, Brivanlou A, Dajani R, Crovace C, Tarricone C, Musacchio A, Roe SM, Pearl L, Greengard P. 2003. GSK-3-selective inhibitors derived from Tyrian purple indirubins. Chem. Biol. 10:1255-1266. http://dx.doi.org/10.1016/j.chembiol.2003.11.010.
127. Woodgett JR. 1990. Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J. 9:2431-2438.
128. Klein PS, Melton DA. 1996. A molecular mechanism for the effect of lithium on development. Proc. Natl. Acad. Sci. U. S. A. 93:8455-8459. http://dx.doi.org/10.1073/pnas.93.16.8455.
129. Coghlan MP, Culbert AA, Cross DA, Corcoran SL, Yates JW, Pearce NJ, Rausch OL, Murphy GJ, Carter PS, Roxbee Cox L, Mills D, Brown MJ, Haigh D, Ward RW, Smith DG, Murray KJ, Reith AD, Holder JC. 2000. Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem. Biol. 7:793-803. http://dx.doi.org/10.1016/S1074-5521(00)00025-9.
130. Gentile G, Merlo G, Pozzan A, Bernasconi G, Bax B, Bamborough P, Bridges A, Carter P, Neu M, Yao G, Brough C, Cutler G, Coffin A, Belyanskaya S. 2012. 5-Aryl-4-carboxamide-1,3-oxazoles: potent and selective GSK-3 inhibitors. Bioorg. Med. Chem. Lett. 22:1989-1994. http://dx.doi.org/10.1016/j.bmcl.2012.01.034.
131. Bhat R, Xue Y, Berg S, Hellberg S, Ormo M, Nilsson Y, Radesater AC, Jerning E, Markgren PO, Borgegard T, Nylof M, Gimenez-Cassina A, Hernandez F, Lucas JJ, Diaz-Nido J, Avila J. 2003. Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. J. Biol. Chem. 278:45937-45945. http://dx.doi.org/10.1074/jbc.M306268200.
132. De Bondt HL, Rosenblatt J, Jancarik J, Jones HD, Morgan DO, Kim SH. 1993. Crystal structure of cyclin-dependent kinase 2. Nature 363:595-602. http://dx.doi.org/10.1038/363595a0.
133. Jeffrey PD, Russo AA, Polyak K, Gibbs E, Hurwitz J, Massague J, Pavletich NP. 1995. Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex. Nature 376:313-320. http://dx.doi.org/10.1038/376313a0.
134. Buss H, Dorrie A, Schmitz ML, Frank R, Livingstone M, Resch K, Kracht M. 2004. Phosphorylation of serine 468 by GSK-3beta negatively regulates basal p65 NF-kappaB activity. J. Biol. Chem. 279:49571-49574. http://dx.doi.org/10.1074/jbc.C400442200.
135. Frame S, Cohen P. 2001. GSK3 takes centre stage more than 20 years after its discovery. Biochem. J. 359:1-16. http://dx.doi.org/10.1042/0264-6021:3590001.
136. Rohr O, Marban C, Aunis D, Schaeffer E. 2003. Regulation of HIV-1 gene transcription: from lymphocytes to microglial cells. J. Leukoc. Biol. 74:736-749. http://dx.doi.org/10.1189/jlb.0403180.
137. Kumar A, Zloza A, Moon RT, Watts J, Tenorio AR, Al-Harthi L. 2008. Active beta-catenin signaling is an inhibitory pathway for human immunodeficiency virus replication in peripheral blood mononuclear cells. J. Virol. 82:2813-2820. http://dx.doi.org/10.1128/JVI.02498-07.
138. Eastman Q, Grosschedl R. 1999. Regulation of LEF-1/TCF transcription factors by Wnt and other signals. Curr. Opin. Cell Biol. 11:233-240. http://dx.doi.org/10.1016/S0955-0674(99)80031-3.
139. Henderson LJ, Narasipura SD, Adarichev V, Kashanchi F, Al-Harthi L. 2012. Identification of novel T cell factor 4 (TCF-4) binding sites on the HIV long terminal repeat which associate with TCF-4, beta-catenin, and SMAR1 to repress HIV transcription. J. Virol. 86:9495-9503. http://dx.doi.org/10.1128/JVI.00486-12.
140. Yao H, Peng F, Fan Y, Zhu X, Hu G, Buch SJ. 2009. TRPC channelmediated neuroprotection by PDGF involves Pyk2/ERK/CREB pathway. Cell Death Differ. 16:1681-1693. http://dx.doi.org/10.1038/cdd.2009.108.
141. Zauli G, Secchiero P, Rodella L, Gibellini D, Mirandola P, Mazzoni M, Milani D, Dowd DR, Capitani S, Vitale M. 2000. HIV-1 Tat-mediated inhibition of the tyrosine hydroxylase gene expression in dopaminergic neuronal cells. J. Biol. Chem. 275:4159-4165. http://dx.doi.org/10.1074/jbc.275.6.4159.
142. Munoz-Montano JR, Lim F, Moreno FJ, Avila J, Diaz-Nido J. 1999. Glycogen synthase kinase-3 modulates neurite outgrowth in cultured neurons: possible implications for neurite pathology in Alzheimer's disease. J. Alzheimers Dis. 1:361-378.
143. Maggirwar SB, Tong N, Ramirez S, Gelbard HA, Dewhurst S. 1999. HIV-1 Tat-mediated activation of glycogen synthase kinase-3beta contributes to Tat-mediated neurotoxicity. J. Neurochem. 73:578-586.
144. Jope RS, Yuskaitis CJ, Beurel E. 2007. Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics. Neurochem. Res. 32:577-595. http://dx.doi.org/10.1007/s11064-006-9128-5.
145. Martin M, Rehani K, Jope RS, Michalek SM. 2005. Toll-like receptormediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nat. Immunol. 6:777-784. http://dx.doi.org/10.1038/ni1221.
146. Kaul M, Lipton SA. 1999. Chemokines and activated macrophages in HIV gp120-induced neuronal apoptosis. Proc. Natl. Acad. Sci. U. S. A. 96:8212-8216. http://dx.doi.org/10.1073/pnas.96.14.8212.
147. Klein RS, Williams KC, Alvarez-Hernandez X, Westmoreland S, Force T, Lackner AA, Luster AD. 1999. Chemokine receptor expression and signaling in macaque and human fetal neurons and astrocytes: implications for the neuropathogenesis of AIDS. J. Immunol. 163:1636-1646.
148. Gonzalez-Scarano F, Martin-Garcia J. 2005. The neuropathogenesis of AIDS. Nat. Rev. Immunol. 5:69-81. http://dx.doi.org/10.1038/nri1527.